Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1284-1290

  Bergman, Philip J ^a   McKnight, Joanne ^a   Novosad, Andrew ^a,c   Charney, Sarah ^a,d   Farrelly, John ^a,e   Craft, Diane ^a   Wulderk, Michelle ^b   Jeffers, Yusuf ^b   Sadelain, Michel ^b   Hohenhaus, Ann E ^a   Segal, Neil ^b   Gregor, Polly ^b   Engelhorn, Manuel ^b   Riviere, Isabelle ^b   Houghton, Alan N ^b   Wolchok, Jedd D ^b  

^a ANIMAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Animal Diagnostic Clinic   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MONOPHENOL MONOOXYGENASE; PLASMID DNA;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; AUTOPSY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; FEMALE; LUNG METASTASIS; MALE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR REJECTION; VACCINATION;

ANIMALS; CANCER VACCINES; COHORT STUDIES; DNA, COMPLEMENTARY; DOGS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MONOPHENOL MONOOXYGENASE; PLASMIDS; RADIOGRAPHY, THORACIC; TIME FACTORS; VACCINES, DNA;

EID: 0037389779     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bostock, D. E. Prognosis after surgical excision of canine melanomas. Vet. Pathol., 16: 32-40, 1979.
2. Harvey, H. J., MacEwen, G., Braun, D., Pamaik, A. K., Withrow, S. J., and Jongeward, S. Prognostic criteria for dogs with oral melanoma. J. Am. Vet. Med. Assoc., 178: 580-582. 1981.
3. MacEwen, E. G., Patnaik, A. K., Harvey, H. J., Hayes, A. A., and Matus, R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Investig., 4: 397-402, 1986.
4. Ramos-Vara, J. A., Beissenherz, M. E., Miller, M. A., Johnson, G. C., Pace, L. W., Fard, A., and Kottler, S. J. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet. Pathol., 37: 597-608, 2000.
5. Schwarz, P. D., Withrow, S. J., Curtis, C. R., Powers, B. E., and Straw, R. C. Mandibular resection as a treatment for oral cancer in 81 dogs. J. Am. Anim. Hosp. Assoc., 27: 601-610, 1991.
6. Schwarz. P. D., Withrow, S. J., Curtis, C. R., Powers, B. E., and Straw, R. C. Partial maxillary resection as a treatment for oral cancer in 61 dogs. J. Am. Anim. Hosp. Assoc., 27: 617-624, 1991.
7. Bateman, K. E., Catton, P. A., Pennock, P. W., and Kruth, S. A. 0-7-21 Radiation therapy for the treatment of canine oral melanoma. J. Vet. Intern. Med., 8: 267-272, 1994.
8. Chapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., Begg, C. B., Agarwala, S. S., Schuchter, L. M., Ernstoff, M. S., Houghton. A. N., and Kirkwood, J. M. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol., 17: 2745-2751, 1999.
9. Houghton, A. N., Meyers, M. L., and Chapman, P. B. Medical treatment of metastatic melanoma. Surg. Clin. N. Am., 76: 1343-1354, 1996.
10. Rassnick, K. M., Ruslander, D. M., Cotter, S. M., Al-Sarraf, R., Bruyette, D. S., Gamblin, R. M., Meleo, K. A., and Moore, A. S. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J. Am. Vet. Med. Assoc., 218: 1444-1448, 2001.
11. MacEwen, E. G. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev., 9: 125-136, 1990.
12. Sirott, M. N., Bajorin, D. F., Wong, G. Y., Tao, Y., Chapman, P. B., Templeton, M. A., and Houghton, A. N. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer (Phila.), 72: 3091-3098, 1993.
13. Pardoll, D. M. Cancer vaccines. Nat. Med., 4: 525-531, 1998.
14. Moelling, K. DNA for genetic vaccination and therapy. Cytokines Cell. Mol. Ther., 3: 127-135, 1997.
15. Chu. R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., and Harding, C. V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med., 186: 1623-1631, 1997.
16. Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth. R. S., Richman, D. D., Carson, D. A., and Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med., 3: 849-854, 1997.
17. Wang, R., Doolan, D. L., Le, T. P., Hedstrom, R. C., Coonan, K. M., Charoenvit, Y., Jones, T. R., Hobart, P., Margalith, M., Ng, J., Weiss, W. R., Sedegah, M., de Taisne, C., Norman, J. A., and Hoffman, S. L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (Wash. DC), 282: 476-480, 1998.
18. Edgeworth, R. L., San, J. H., Rosenzweig, J. A., Nguyen, N. L., Boyer, J. D., and Ugen. K. E. Vaccine development against HIV-1: current perspectives and future directions. Immunol. Res., 25: 53-74, 2002.
19. Perales, M. A., Blachere, N. E., Engelhorn, M. E., Ferrone, C. R., Gold, J. S., Gregor, P. D., Noffz, G., Wolchok, J. D., and Houghton, A. N. Strategies to overcome immune ignorance and tolerance. Semin. Cancer Biol., 12: 63-71. 2002.
20. Weber, L. W., Bowne, W. B., Wolchok, J. D., Srinivasan, R., Qin, J., Moroi, Y., Clynes, R., Song, P., Lewis, J. J., and Houghton, A. N. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Investig., 102: 1258-1264, 1998.
21. Bouchard, B., Fuller, B. B., Vijayasaradhi, S., and Houghton, A. N. Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J. Exp. Med., 169: 2029-2042, 1989.
22. Wang, S., Bartido, S., Yang, G., Qin, J., Moroi, Y., Panageas, K. S., Lewis, J. J., and Houghton, A. N. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J. Immunol., 163: 5820-5826, 1999.
23. Bowne, W. B., Srinivasan, R., Wolchok, J. D., Hawkins, W. G., Blachere, N. E., Dyall, R., Lewis, J. J., and Houghton, A. N. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med., 190: 1717-1722, 1999.
24. Wolchok, J. D., and Livingston, P. O. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol., 2: 205-211, 2001.
25. Aguiar, J. C., Hedstrom, R. C., Rogers, W. O., Charoenvit, Y., Sacci, J. B., Jr., Lanar, D. E., Majam, V. F., Stout, R. R., and Hoffman, S. L. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine, 20: 275-280, 2001.
26. Williams, J., Fox-Leyva, L., Christensen, C., Fisher, D., Schlicting, E., Snowball, M., Negus, S., Mayers, J., Koller, R., and Stout, R. Hepatitis A vaccine administration: comparison between jet- injector and needle injection. Vaccine, 18: 1939-1943, 2000.
27. Fleming, T. R., and Lin, D. Y. Survival analysis in clinical trials: past developments and future directions. Biometrics, 56: 971-983, 2000.
28. Vijayasaradhi, S., Bouchard, B., and Houghton, A. N. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J. Exp. Med., 171: 1375-1380, 1990.
29. Greten, T. F., and Jaffee, E. M. Cancer vaccines. J. Clin. Oncol., 17: 1047-1060, 1999.
30. Chan, A. D., and Morton, D. L. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin. Oncol., 25: 611-622, 1998.
31. MacEwen, E. G., Kurzman, I. D., Vail, D. M., Dubielzig, R. R., Everlith, K., Madewell, B. R., Rodriguez, C. O. J., Phillips, B., Zwahlen, C. H., Obradovich, J., Rosenthal, R. C., Fox, L. E., Rosenberg, M., Henry, C., and Fidel, J. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 5: 4249-4258, 1999.
32. Hogge, G. S., Burkholder, J. K., Culp, J., Albertini, M. R., Dubielzig, R. R., Yang, N. S., and MacEwen, E. G. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther., 6: 26-36, 1999.
33. Hogge, G. S., Burkholder, J. K., Culp, J., Albertini, M. R., Dubielzig, R. R., Keller, E. T., Yang, N. S., and MacEwen, E. G. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum. Gene Ther., 9: 1851-1861, 1998.
34. Quintin-Colonna, F., Devauchelle, P., Fradelizi, D., Mourot, B., Faure, T., Kourilsky, P., Roth, C., and Mehtali, M. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther., 3: 1104-1112, 1996.
35. Dow, S. W., Elmslie, R. E., Willson, A. P., Roche, L., Gorman, C., and Potter, T. A. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J. Clin. Investig., 101: 2406-2414. 1998.
36. Fernandez, N., Duffour, M. T., Perricaudet, M., Lotze, M. T., Tursz, T., and Zitvogel, L. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines Cell. Mol. Ther., 4: 53-65. 1998.